Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rectus abdominis muscle endometriotic mass in a woman affected by multiple sclerosis.
Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.
The role of growth factors as a therapeutic approach to demyelinating disease.
Is it time for a new global classification of multiple sclerosis?
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
Ximino
Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.
Biplanar MRI for the assessment of the spinal cord in multiple sclerosis.
[Immunodepressive therapy in neurology].
Multiple sclerosis relapses and depression.
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Epidural blood patch in a patient with multiple sclerosis: is it safe?
Drug record: Amiloride
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
A biopsychosocial model of resilience for multiple sclerosis.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
Juxtacortical Lesions in Multiple Sclerosis: Assessment of Gray Matter Involvement Using Phase Difference-enhanced Imaging (PADRE).
Frequent but nonspecific venous narrowing in paediatric multiple sclerosis.
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter.

Pages